A Phase 2 Randomized Trial of Mezagitamab in Primary Immune Thrombocyt

Short summary:
In this study, people taking mezagitamab and placebo had similar rates of side effects. Serious side effects were slightly more common with mezagitamab, but overall safety was comparable between the groups. The average starting platelet counts were also similar. By week 16, the 600-mg mezagitamab dose showed a much stronger platelet response, with 91% of participants improving compared with 23% in the placebo group.
Conclusions
Treatment with mezagitamab led to increased platelet counts, with a safety profile that appeared to be similar to that of placebo among participants with persistent or chronic ITP.
https://www.nejm.org/doi/10.1056/NEJMoa2513120